Qureight is an end-to-end imaging CRO company on a mission to accelerate clinical trials. We provide enterprise-grade imaging and precision endpoints for the biopharmaceutical industry. Our AI-powered data and imaging curation platform permits the analysis of clinical imaging and other healthcare data from patients with lung and heart disease, helping our customers bring treatments to market, faster. We provide automated image management and AI analysis in therapeutic areas such as Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Bronchiectasis, and Pulmonary Hypertension. Our world-leading team of scientists, engineers and clinicians is based in Cambridge, UK.
Qureight
- Life Sciences
- Cambridge, United Kingdom
- £15m
- qureight.com
- Update Information
More venture news
- 29 Jul 2026

QureightQureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease
Series BLife Sciences - 7 Jul 2026

Healome TherapeuticsHealome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease
SeedLife Sciences - 6 Jul 2026

Revolver TherapeuticsRevolver Therapeutics raises £600k in funding led by QantX to develop peptides that shut down cancer-driving proteins
EquityLife Sciences
